FDA is notifying healthcare professionals as well as patients for the voluntary recalls of ranitidine drugs. These medicines are being recalled as they may possibly contain unacceptable levels of N-nitrosodimethylamine (NDMA). N-nitrosodimethylamine (NDMA) is an ingredient the World Health Organization has categorized as a "probable human carcinogen" that can cause cancer.
Ranitidine is an OTC (over-the-counter) & prescription drug with H2 (histamine-2) blocker that is mainly used for decreasing the amount stomach acid. OTC ranitidine has been approved of preventing as well as relieving heartburn accompanying acid ingestion followed by sour stomach. Prescription ranitidine is approved for numerous symptoms, comprising treatment plus prevention of stomach & intestine ulcers.
However, recent recalls in terms of ranitidine, posted by the Food and Drug Administration (FDA) lately, are the latest in a series that initiated in September 2019, when the FDA alerted the public to the presence of a probable human carcinogen, N-Nitrosodimethylamine (NDMA), in a few ranitidine medications. Ranitidine is the generic form of Zantac that is obtainable over the counter & by prescription.
The FDA's declaration impelled national drugstore chains to pull ranitidine medications from their shelves “out an abundance of caution.” Several drug manufacturers followed with voluntary recalls for their medications. Now, more are joining the line including Appco Pharma LLC as well as Northwind Pharmaceuticals who are voluntarily recalling prescription ranitidine hydrochloride capsules & ranitidine tablets (150 mg and 300 mg, manufactured by Glenmark Pharmaceutical Inc.) respectively. Also, giants like Denton Pharma Inc.and Mylan Pharmaceuticals have also started recalling all of its unexpired ranitidine tablets plus nizatidine capsules respectively.
All of these companies referred to NDMA as impurities in the pills as key reason for recalls, however have even claimed for no adverse health effects reported until now due to these medicines. In addition, patients are still being advised to stop taking these medications immediately. Nevertheless, a number of other common drugs used for heartburn & ulcer drugs are still approved by the regulatory bodies that include Tagamet (cimetidine), Pepcid (famotidine), Nexium (esomeprazole, Prilosec (omeprazole) and Prevacid (lansoprazole).
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Severity: Warning
Message: count(): Parameter must be an array or an object that implements Countable
Filename: amp/news_details_amp.php
Line Number: 252
Backtrace:
File: /home/smartmarketnews/public_html/application/views/amp/news_details_amp.php
Line: 252
Function: _error_handler
File: /home/smartmarketnews/public_html/application/controllers/Amp_controller.php
Line: 41
Function: view
File: /home/smartmarketnews/public_html/index.php
Line: 315
Function: require_once
Smarter Decisions with Smart News
Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.
media@smartmarketnews.com | sales@smartmarketnews.com
Contact Us